Antibody

7개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved7 programs
AntibodyCurated CorestaleAmgenPhase 3

Blinatumomab (Blinatumomab)

B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 115Status Recruiting
AntibodyLimited DatastaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 2Status Recruiting
AntibodyLimited DatastaleAmgenPhase 2

MT103 (Blinatumomab, Blinatumomab (MT103))

Non-Hodgkin's Lymphoma, Relapsed · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 2Status Active
AntibodyLimited DatastaleJanssenPhase 1

daratumumab (Darzalex, Indium In 111-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 2Status Recruiting
AntibodyLimited DatastaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#AcuteLymphoblasticLeukemia+2
Trials 1Status Recruiting
AntibodyLimited DatastalePfizerPhase 3

Inotuzumab (Inotuzumab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase3#monoclonal-antibody#Pfizer
Trials 1Status Discontinued
AntibodyLimited DatastaleAmgenPhase 1

blinatumomab and auto-HSCT "sandwich " strategy (blinatumomab and auto-HSCT "sandwich " strategy)

B-cell Acute Lymphoblastic Leukemia · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#Antibody#Phase1#monoclonal-antibody#Amgen
Trials 1Status Recruiting